Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
FAIL · Does not pass the screen
66.74 USD
At the last full screen 2026-09-11
Screened 2026-09-11 · the tape above runs as of 21:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
Liquidia Corporation holds its Markdown at $66.74. Consolidating, no directional conviction, held for 12 days.
As held on the ledger · 2026-09-11
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 12 days
Price at the screen
$66.74
Valuation
47.67 trailing · 11.81 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.54
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
60.36%
Below 33%
Interest-bearing debt is 60.4% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
74.64%
Below 49%
Money owed to the company is 74.6% of assets, above the 49% limit.
Fail
Revenue purity
4.18%
Below 5%
Only 4.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-11 screen. The gold marker is the market price at the same screen. A 74.8% margin of safety to the base estimate.
Third-party analyst targets: 8 covering, consensus Buy. The average target sits +63% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-11 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Rare lung drug launch sparks explosive revenue jump
A patient with pulmonary hypertension gets a new inhaled option that bypasses hospital pumps and daily infusions. Liquidia has turned that need into a product now driving revenue growth above 4000 percent, with an 8 percent profit margin and 28 percent return on equity. The ethical screen clears, yet our opportunity rating stays at none because the market price already sits near our fair value.
Forward earnings sit at 14.3 times, which looks reasonable next to the growth, but eight analysts still cluster around a 70 dollar median target well below the current quote. The business remains a single-product story in a narrow rare-disease niche, so any slip in uptake or reimbursement quickly resets the numbers.
Unknown competitive defences and typical biotech execution risks sit alongside currency and regulatory swings common to specialty drugs. The setup rewards close watching rather than immediate commitment. Analysis, not advice.
The risks · The things to watch: as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
LQDA trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-04Markdown · changed$70.49-16.2%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 16.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 82% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 337%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (8 analysts) rates it none, with a mean price target of $65.
2026-08-04Markup$84.11+18.1%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 18.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 82% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 337%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (8 analysts) rates it none, with a mean price target of $65.
2026-07-18Markup$71.23+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 82% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 337%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (8 analysts) rates it none, with a mean price target of $65.
2026-07-03Markup$71.23+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$71.23Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
